Shortage of Midazolam Hydrochloride Injection
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Midazolam Hydrochloride Injection is experiencing a current shortage for some presentations, as reported by the FDA, affecting certain manufacturers while others remain available.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Midazolam Hydrochloride Injection.
Shortage of Midazolam Hydrochloride Injection
What's in Shortage
The drug in shortage is Midazolam Hydrochloride Injection, with brand names MIDAZOLAM and MIDAZOLAM IN SODIUM CHLORIDE. It is available in injection dosage form and falls under the therapeutic categories of Anesthesia and Neurology. The shortage status is current, with the initial posting date of 04/02/2020 and last updated on 04/02/2026.
Which Manufacturers Are Affected
Several manufacturers are involved with varying availability statuses:
- Fresenius Kabi USA, LLC: Available for some presentations (e.g., Midazolam Hydrochloride, Injection, 1 mg/1 mL - NDC 63323-411-12 and NDC 63323-411-25), but unavailable for others (e.g., Midazolam Hydrochloride, Injection, 5 mg/1 mL - NDC 63323-412-10 and NDC 63323-411-10; expected recovery: TBD for some, next release April 2026 for NDC 63323-412-25). Contact: 888-386-1300.
- Hospira, Inc., a Pfizer Company: Available for multiple presentations (e.g., Midazolam Hydrochloride, Injection, 25 mg/5 mL; Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL; 5 mg/5 mL; 10 mg/2 mL; 5 mg/mL; and 10 mg/10 mL). Contact: 844-646-4398.
- WG Critical Care: Available for presentations (e.g., Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL - NDC 44567-610-10 and NDC 44567-611-10). Related info: Please check wholesalers and distributors for inventory. Contact: 888-493-0861.
Why There's a Shortage
No specific reason for the shortage has been provided in the available data.
What Patients Should Do
If you rely on this medication, speak with your pharmacist to check for availability in your area. You may also ask your healthcare provider for guidance on managing your treatment. Contact the relevant manufacturer using the provided contact information if needed. Remember, patients should consult their healthcare provider for any medical advice and not make changes to their treatment without professional input.
Source
This information is sourced from the FDA Drug Shortage Database, last updated on 04/02/2026.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (2,062 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.